Palleon Pharmaceuticals

Palleon Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases by targeting glycan-mediated immune regulation. Founded on Nobel laureate Carolyn Bertozzi's groundbreaking research in glycobiology, the company has established a portfolio of first-in-class drug candidates based on its proprietary EAGLE and HYDRA platforms. These technologies address the historical challenges of targeting glycans in drug development, paving the way for a new era of treatment options for diseases where immune system dysfunction plays a major role.

Palleon's lead program, E-602, a first-in-class glyco-immune checkpoint inhibitor, is currently being evaluated in a Phase 1/2 clinical trial for patients with advanced cancers. The company is also developing a broad pipeline of drug candidates targeting Siglecs and other glycan-sensing receptors that may have applications in inflammatory diseases such as autoimmunity and fibrosis. Palleon's commitment to advancing a completely new modality for fighting disease, coupled with its exceptional scientific team and advanced platform technologies, positions the company as a leading force in the field of glyco-immunology.

Palleon Pharmaceuticals offers a range of benefits to its employees, including a collaborative and supportive work environment, opportunities for professional growth, and a commitment to improving the lives of patients. The company fosters a culture of collaboration and innovation, as evidenced by the positive feedback from current employees about the leadership team, their colleagues, and the company's mission. Palleon is a growing organization with a strong commitment to its employees, offering boundless opportunities for professional development within a dynamic and rewarding workplace.

Palleon Pharmaceuticals is a biotechnology company pioneering the development of glyco-immunology drugs to treat cancer and inflammatory diseases. Their mission is to revolutionize the treatment of these conditions by targeting the intricate role of sugar molecules (glycans) on the surface of cells in regulating the immune system. Palleon's innovative approach aims to unlock new therapeutic opportunities for patients who haven't responded well to existing treatments, ultimately improving their lives and extending their life expectancy.

Palleon Pharmaceuticals promotes a culture of collaboration, innovation, and passion. They value their employees, fostering a friendly and supportive work environment where everyone feels valued and empowered to do their best work. This collaborative spirit is evident in their commitment to teamwork, with employees sharing a common goal of improving patient lives through groundbreaking glycobiology research.

Palleon Pharmaceuticals is committed to fostering a diverse, equitable, and inclusive workplace. They recognize the value of diverse perspectives and experiences and strive to create an environment where all employees feel respected, valued, and empowered. Their website highlights the diverse backgrounds and perspectives of their employees, emphasizing the importance of collaboration and a culture that welcomes contributions from all. Palleon actively works to build a team that reflects the diversity of the patients they serve.